Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract 1851: Selective targeting of aberrant ETS transcription factors using uniquely modified mithramycin analogs

Markos Leggas, Ambika Dudhate, Jurgen Rohr

Cancer Res (2022) 82 (12_Supplement): 1851.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1851

Published: 15 June 2022

View article

Journal Articles

Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors

James Geller, Patrick Thompson, Javier Oesterheld, Dennis M. Brown, Jeffrey Bacha, Sarath Kanekal, Lorena Lopez, Markos Leggas, Neil Sankar, Noymi Yam, Lars M. Wagner

Cancer Res (2022) 82 (12_Supplement): CT256.

DOI: https://doi.org/10.1158/1538-7445.AM2022-CT256

Published: 15 June 2022

View article

Journal Articles

Abstract A41: Novel mithramycin analogues with improved pharmacologic profile and efficacy in ETS transcription factor-driven tumors

Markos Leggas, Joseph Eckenrode, Yang Liu, Abhisek Mandal, Reiya Hayden, Oleg Tsodikov, Jon Thorson, Jurgen Rorh

Cancer Res (2020) 80 (14_Supplement): A41.

DOI: https://doi.org/10.1158/1538-7445.PEDCA19-A41

Published: 15 July 2020

View article

Journal Articles

Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding

Reiya C. Hayden, Caixia Hou, Prithiba Mitra, Abhisek Mandal, Jurgen Rohr, Jon Thorson, Oleg Tsodikov, Markos Leggas

Cancer Res (2019) 79 (13_Supplement): 2954.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2954

Published: 01 July 2019

View article

Journal Articles

Abstract 2628: Mithramycin analogs with reduced toxicity for EWS-FLI1 targeting

Joseph Eckenrode, Jamie Horn, Jhong-Min Chen, Jurgen Rohr, Markos Leggas

Cancer Res (2015) 75 (15_Supplement): 2628.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2628

Published: 01 August 2015

View article

Journal Articles

Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients

Tamer Ahmed, John Hayslip, Markos Leggas

Cancer Res (2012) 72 (8_Supplement): 3778.

DOI: https://doi.org/10.1158/1538-7445.AM2012-3778

Published: 15 April 2012

View article

Journal Articles

Abstract 3547: In vitro and ex vivo anti-leukemia activity of AR-67, a novel lipophilic camptothecin

Eleftheria Tsakalozou, Dianna Howard, Markos Leggas

Cancer Res (2011) 71 (8_Supplement): 3547.

DOI: https://doi.org/10.1158/1538-7445.AM2011-3547

Published: 15 April 2011

View article

Journal Articles

Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution

Kazumasa Takenaka, Jessica A. Morgan, George L. Scheffer, Masashi Adachi, Clinton F. Stewart, Daxi Sun, Markos Leggas, Karin F.K. Ejendal, Christine A. Hrycyna, John D. Schuetz

Cancer Res (2007) 67 (14): 6965–6972.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-4720

Published: 17 July 2007

View article

Includes: Supplementary data

Journal Articles

Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo

Markos Leggas, John C. Panetta, Yanli Zhuang, John D. Schuetz, Brad Johnston, Feng Bai, Brian Sorrentino, Sheng Zhou, Peter J. Houghton, Clinton F. Stewart

Cancer Res (2006) 66 (9): 4802–4807.

DOI: https://doi.org/10.1158/0008-5472.CAN-05-2915

Published: 01 May 2006

View article

Journal Articles

Comparative pharmacokinetics in mice of the novel camptothecin analog DB-67 administered in diluted cremophor/ethanol or a supersaturated solution stabilized by a chemically-modified cyclodextrin.

Markos Leggas, Jamie Horn, Sherri Jordan, Michael J. Roberts, Bradley D. Anderson

Cancer Res (2006) 66 (8_Supplement): 1302.

Published: 15 April 2006

View article

Journal Articles

Immunohistochemical analysis of multidrug resistance associated protein-4 (MRP4) expression in human normal and tumor tissues

Markos Leggas, Rodica P. Bunaciu, Michael J. Roberts, Guoqing Du, Jatinder Lamba, George L. Scheffer, Clinton F. Stewart, John D. Schuetz

Cancer Res (2006) 66 (8_Supplement): 141.

Published: 15 April 2006

View article

Journal Articles

Functional interaction between Mrp4 (abcc4) and Bcrp (abcg2) as revealed by the single and double-knockout mouse

Kazumasa Takenaka, Jessica Morgan, Masashi Adachi, Daxi Sun, Clinton Stewart, Markos Leggas, Karin F Ejendal, Christine A Hrycyna, John D Schuetz

Cancer Res (2006) 66 (8_Supplement): 144.

Published: 15 April 2006

View article

Journal Articles

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Clinton F. Stewart, Markos Leggas, John D. Schuetz, John C. Panetta, Pamela J. Cheshire, Jennifer Peterson, Najat Daw, Jesse J. Jenkins, III, Richard Gilbertson, Glen S. Germain, Franklin C. Harwood, Peter J. Houghton

Cancer Res (2004) 64 (20): 7491–7499.

DOI: https://doi.org/10.1158/0008-5472.CAN-04-0096

Published: 15 October 2004

View article

Journal Articles

Gefitinib (’Iressa’, ZD1839) is a BCRP and MDR1 inhibitor.

Markos Leggas, John D. Schuetz, John C. Panetta, Brad Johnston, Feng Bai, Sheng Zhou, Brian Sorrentino, Christopher M. Waters, Peter J. Houghton, Clinton F. Stewart

Cancer Res (2004) 64 (7_Supplement): 568.

Published: 01 April 2004

View article

Journal Articles

Multidrug resistance protein 4 (Mrp4) is expressed at the blood-cerebrospinal and blood-brain barriers and restricts topotecan brain penetration

Markos Leggas, Masashi Adachi, Daxi Sun, Guoqing Du, Kelly E. Mercer, John C. Panetta, Yanli Zhuang, George L. Scheffer, Rik J. Scheper, Peter Wielinga, Piet Borst, Clinton F. Stewart, John D. Schuetz

Cancer Res (2004) 64 (7_Supplement): 115–116.

Published: 01 April 2004

View article

NARROW

Abstract 1851: Selective targeting of aberrant ETS transcription factors using uniquely modified mithramycin analogs

Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Abstract A41: Novel mithramycin analogues with improved pharmacologic profile and efficacy in ETS transcription factor-driven tumors

Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding

Abstract 2628: Mithramycin analogs with reduced toxicity for EWS-FLI1 targeting

Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients

Abstract 3547: In vitro and ex vivo anti-leukemia activity of AR-67, a novel lipophilic camptothecin

Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution

Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo

Comparative pharmacokinetics in mice of the novel camptothecin analog DB-67 administered in diluted cremophor/ethanol or a supersaturated solution stabilized by a chemically-modified cyclodextrin.

Immunohistochemical analysis of multidrug resistance associated protein-4 (MRP4) expression in human normal and tumor tissues

Functional interaction between Mrp4 (abcc4) and Bcrp (abcg2) as revealed by the single and double-knockout mouse

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Gefitinib (’Iressa’, ZD1839) is a BCRP and MDR1 inhibitor.

Multidrug resistance protein 4 (Mrp4) is expressed at the blood-cerebrospinal and blood-brain barriers and restricts topotecan brain penetration

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only